Hahn Mark W's Form 4 filing

Verona Pharma plc (VRNA) · filed Nov 3, 2022

Accession no.: 0001104659-22-114412
Filed: Nov 3, 2022
Trade date: Nov 1, 2022
Filing delay: 2 days
Rule 10b5-1 plan: Not on the form (before 2023)

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $22.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Hahn Mark WCIK 0001408502	Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Nov 1, 2022	Ordinary Shares	FTax withholdingDisposed	−454,856	$1.60^F3	−$727,769.6	17,458,640	Direct
Nov 1, 2022	Ordinary Shares	SSaleDisposed	−13,160	$1.67^F5	−$21,977.2	17,445,480	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8).

Referenced by the price of 1 transaction in Table I.

The price reported represents the sale price of the ADSs divided by eight (8).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)